The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs
Abstract
OBJECTIVE: The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0.02% to 2.44%. DATA SOURCES: MEDLINE search conducted in January 2003 and review of references within the retrieved articles. DATA SYNTHESIS: Our MEDLINE research yielded 68 cases (21 females and 47 males) of NMS associated with atypical antipsychotic drugs (clozapine, N = 21; risperidone, N = 23; olanzapine, N = 19; and quetiapine, N = 5). The fact that 21 cases of NMS with clozapine were found indicates that low occurrence of extrapyramidal symptoms (EPS) and low EPS-inducing potential do not prevent the occurrence of NMS and D(2) dopamine receptor blocking potential does not have direct correlation with the occurrence of NMS. One of the cardinal features of NMS is an increasing manifestation of EPS, and the conventional antipsychotic drugs are known to produce EPS in 95% or more of NMS cases. With atypical antipsychotic drugs, the incidence of EPS during NMS is of a similar magnitude. CONCLUSIONS: For NMS associated with atypical antipsychotic drugs, the mortality rate was lower than that with conventional antipsychotic drugs. However, the mortality rate may simply be a reflection of physicians' awareness and ensuing early treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroleptic malignant syndrome
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.10.1137 · Cited by 978
Neuroleptic malignant syndrome
Caroff, S. N., & Mann, S. C. (1993) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30278-4 · Cited by 514
Kane, J. M. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.133 · Cited by 323
A prospective analysis of 24 episodes of neuroleptic malignant syndrome
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.6.717 · Cited by 292
Neuroleptic malignant syndrome: review and analysis of 115 cases
Addonizio, G., Susman, V. L., & Roth, S. D. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90010-2 · Cited by 286
The neuroleptic malignant syndrome: agent and host interaction
Shalev, A., & Munitz, H. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb02694.x · Cited by 261
Clozapine-Induced Neuroleptic Malignant Syndrome: Review and Report of New Cases
Sachdev, P. S., Kruk, J., Kneebone, M., & Kissane, D. W. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00010 · Cited by 150
Clozapine-Associated Neuroleptic Malignant Syndrome: Two New Cases and a Review of the Literature
Karagianis, J. L., Phillips, L., Hogan, K. P., et al. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18286 · Cited by 132
[Neuroleptic malignant syndrome].
Gázquez, J. M. C. D. L. B., Montero‐Pérez, F. J., Sánchez Medina, C., & Murillo, L. M. J. (1992) · PubMed · Cited by 124
Atypical Antipsychotics and Neuroleptic Malignant Syndrome
Caroff, S. N., Mann, S. C., & Campbell, E. C. (2000) · Psychiatric Annals · doi:10.3928/0048-5713-20000501-09 · Cited by 104
Essentials of Clinical Psychopharmacology
(2006) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585623167 · Cited by 95
Clinical Management of Neuroleptic Malignant Syndrome
Susman, V. L. (2001) · Psychiatric Quarterly · doi:10.1023/a:1010389215197 · Cited by 88
Suzuki, A., Kondo, T., Otani, K., Mihara, K., Yasui-Furukori, N., Sano, A., Koshiro, K., & Kaneko, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1714 · Cited by 80
Clozapine-induced neuroleptic malignant syndrome.
Dasgupta, K., & Young, A. S. (1991) · PubMed · Cited by 67
Neuroleptic Rechallenge after Neuroleptic Malignant Syndrome: Case Report and Literature Review
Wells, A. J., Sommi, R. W., & Crismon, M. L. (1988) · Annals of Pharmacotherapy · doi:10.1177/106002808802200606 · Cited by 66
Neuroleptic Malignant Syndrome and Quetiapine
SING, K. J., RAMAEKERS, G. M. G. I., & van Harten, P. N. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.149 · Cited by 59
Marked Elevation of Serum Creatine Kinase Associated with Olanzapine Therapy
Marcus, E., Vass, Á., & Zislin, J. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18282 · Cited by 58
Neuroleptic Malignant Syndrome Associated with Olanzapine
Johnson, V., & Bruxner, G. (1998) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679809073880 · Cited by 57
A case of clozapine-induced neuroleptic malignant syndrome.
Miller, D. D., Sharafuddin, M. J., & Kathol, R. G. (1991) · PubMed · Cited by 55
Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies
Sechi, G., Agnetti, V., Masuri, R., Deiana, G. A., Pugliatti, M., Paulus, K. S., & Rosati, G. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00123-8 · Cited by 53
Risperidone-Induced Neuroleptic Malignant Syndrome: A Case Report and Review
Meterissian, G. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100112 · Cited by 49
Neuroleptic malignant syndrome associated with clozapine use.
Anderson, E. S., & Powers, P. S. (1991) · PubMed · Cited by 45
Neuroleptic Malignant Syndrome Associated with Clozapine Treatment
Tsai, G. E., Crisostomo, G., Rosenblatt, M., et al. (1995) · Annals of Clinical Psychiatry · doi:10.3109/10401239509149033 · Cited by 45
Risperidone-Induced Neuroleptic Malignant Syndrome in an Adolescent
Robb, A. S., CHANG, W., LEE, H. K., & COOK, M. S. (2000) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2000.10.327 · Cited by 45
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment
Järventausta, K., & Leinonen, E. V. J. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102003231.x · Cited by 40
Risperidone-induced neuroleptic malignant syndrome in young patient
Raitasuo, V., Vataja, R., & Elomaa, E. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90489-8 · Cited by 40
Atypical Neuroleptic Malignant Syndrome Associated with Olanzapine
Reeves, R. R., Torres, R. A., Liberto, V., & Hart, R. H. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.8.641.33211 · Cited by 37
Neuroleptic Malignant Syndrome After the Initiation of Olanzapine
Levenson, J. L. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00016 · Cited by 29
Hatch, C. D., Lund, B. C., & Perry, P. J. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.11.1003.34528 · Cited by 28
Lee, H., Ryan, J. M., Mullett, G., et al. (1994) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470090410 · Cited by 28
Olanzapine Usage Associated With Neuroleptic Malignant Syndrome
Philibert, R. A., Adam, L. A., Frank, F. M., & Carney, C. P. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.6.528 · Cited by 28
Recognition, assessment and management of neuroleptic malignant syndrome.
Khan, M. O., & Farver, D. (2000) · PubMed · Cited by 21
A Case of Delayed NMS Induced by Risperidone
Lee, M. S., Lee, H., & Kim, L. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.2.254-a · Cited by 16
Clozapine-Associated Neuroleptic Malignant Syndrome
Baciewicz, A. M., Chandra, R., & Whelan, P. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_1-200209030-00034 · Cited by 13
Cited by
Neuroleptic Malignant Syndrome
Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.870 · Cited by 579
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Modern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Metadata
- Authors
- Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K., & Sidhom, T.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-04-15
- Volume
- 65
- Issue
- 4
- Pages
- 464-470
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2031792451
- Cited by
- 273
- References
- 34
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.